Replies to post #247470 on Biotech Values

[DewDiligence]

OMER—(-30%)—misses primary endpoint in Narsoplimab phase-3 trial:

https://finance.yahoo.com/news/omeros-corporation-provides-interim-analysis-113000110.html

Omeros Corporation…today provided an update regarding the interim analysis outcome in ARTEMIS-IGAN, the Company’s Phase 3 trial evaluating narsoplimab for the treatment of immunoglobulin A (IgA) nephropathy.

The primary endpoint is reduction in proteinuria assessed by 24-hour urine protein excretion (UPE) at 36 weeks compared to placebo in the intent-to-treat population of 180 IgA nephropathy patients with high baseline proteinuria (24-hour UPE > 2 g/day). Topline results show that narsoplimab did not achieve statistically significant improvement over placebo.